{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:48Z","timestamp":1793148348255,"version":"4.5.0"},"reference-count":212,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic sclerosis and autoimmune myositis are both associated with decreased quality of life and increased mortality. Their prognosis and management largely depend on the disease subgroups. Indeed, systemic sclerosis is a heterogeneous disease, the two predominant forms of the disease being limited and diffuse scleroderma. Autoimmune myositis is also a heterogeneous group of myopathies that classically encompass necrotizing myopathy, antisynthetase syndrome, dermatomyositis and inclusion body myositis. Recent data revealed that an additional disease subset, denominated \u201cscleromyositis\u201d, should be recognized within both the systemic sclerosis and the autoimmune myositis spectrum. We performed an in-depth review of the literature with the aim of better delineating scleromyositis. Our review highlights that this concept is supported by recent clinical, serological and histopathological findings that have important implications for patient management and understanding of the disease pathophysiology. As compared with other subsets of systemic sclerosis and autoimmune myositis, scleromyositis patients can present with a characteristic pattern of muscle involvement (i.e. distribution of muscle weakness) along with multisystemic involvement, and some of these extra-muscular complications are associated with poor prognosis. Several autoantibodies have been specifically associated with scleromyositis, but they are not currently integrated in diagnostic and classification criteria for systemic sclerosis and autoimmune myositis. Finally, striking vasculopathic lesions at muscle biopsy have been shown to be hallmarks of scleromyositis, providing a strong anatomopathological substratum for the concept of scleromyositis. These findings bring new insights into the pathogenesis of scleromyositis and help to diagnose this condition, in patients with subtle SSc features and\/or no autoantibodies (i.e. \u201cseronegative\u201d scleromyositis). No guidelines are available for the management of these patients, but recent data are showing the way towards a new therapeutic approach dedicated to these patients.<\/jats:p>","DOI":"10.3389\/fimmu.2022.974078","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T09:53:56Z","timestamp":1674726836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis"],"prefix":"10.3389","volume":"13","author":[{"given":"Margherita","family":"Giannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ellezam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Leclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Troyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Sen\u00e9cal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Geny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Landon-Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2013.11.004","article-title":"Diagnostic criteria of systemic sclerosis","author":"Hudson","year":"2014","journal-title":"J Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24676","article-title":"Health-related quality of life in systemic sclerosis: a systematic review","volume":"61","author":"Hudson","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160753","article-title":"Health-related quality of life (HRQoL) in idiopathic inflammatory myopathy: A systematic review","volume":"11","author":"Leclair","year":"2016","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: Results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: Data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jbspin.2017.03.005","article-title":"Inflammatory myopathies: A new landscape","volume":"85","author":"Meyer","year":"2018","journal-title":"Joint Bone Spine."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: Is there anything left? a retrospective diagnostic review from a tertiary myositis centre","volume":"60","author":"Loarce-Martos","year":"2021","journal-title":"Rheumatology."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.61.3.288","article-title":"Unicorns, dragons, polymyositis, and other mythological beasts","volume":"61","author":"Amato","year":"2003","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.08.008","article-title":"Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: Retrospective study of 169 patients","volume":"77","author":"V\u00e1ncsa","year":"2010","journal-title":"Joint Bone Spine."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108616","article-title":"Antinuclear antibody with distinct specificity for polymyositis","volume":"59","author":"Wolfe","year":"1977","journal-title":"J Clin Invest."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1257::AID-ART10>3.0.CO;2-R","article-title":"Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies","volume":"40","author":"Hausmanowa-Petrusewicz","year":"1997","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League against Rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/ar4562","article-title":"Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: A descriptive study on clinical features and myopathology","volume":"16","author":"Bhansing","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key343","article-title":"The performance of the European league against Rheumatism\/American college of rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort","volume":"58","author":"Parker","year":"2019","journal-title":"Rheumatol (Oxford)."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12840","article-title":"Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis","volume":"48","author":"Ellezam","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab492","article-title":"Autoantibody profiles delineate distinct subsets of scleromyositis","volume":"61","author":"Leclair","year":"2022","journal-title":"Rheumatol (Oxford)."},{"key":"B22","article-title":"ACR\/EULAR criteria for myositis and systemic sclerosis lack sensitivity for scleromyositis [abstract]","volume":"71","author":"Meyer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: The frequency of severe organ complications in systemic sclerosis","volume":"40","author":"Muangchan","year":"2013","journal-title":"A systematic review. J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1759720X16671928","article-title":"Histopathological findings in systemic sclerosis-related myopathy: Fibrosis and microangiopathy with lack of cellular inflammation","volume":"9","author":"Corallo","year":"2017","journal-title":"Ther Adv Musculoskeletal."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02305-3","article-title":"Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology","volume":"141","author":"Siegert","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/0002-8703(93)90075-K","article-title":"Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association","volume":"125","author":"Follansbee","year":"1993","journal-title":"Am Heart J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.095919","article-title":"A descriptive and prognostic study of systemic sclerosis-associated myopathies","volume":"68","author":"Ranque","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3109\/03009741003774626","article-title":"Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features","volume":"39","author":"Ranque","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2013.868512","article-title":"Myopathy is a poor prognostic feature in systemic sclerosis: Results from the Canadian scleroderma research group (CSRG) cohort","volume":"43","author":"Jung","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780110405","article-title":"Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)","volume":"11","author":"Medsger","year":"1968","journal-title":"Arthritis Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.28.3.281","article-title":"Skeletal muscle involvement in systemic sclerosis","volume":"28","author":"Thompson","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/art.1780210111","article-title":"Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations","volume":"21","author":"Clements","year":"1978","journal-title":"Arthritis Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780250110","article-title":"Electromyographic findings in various forms of progressive systemic sclerosis","volume":"25","author":"Hausmanowa-Petrusewicz","year":"1982","journal-title":"Arthritis Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780240506","article-title":"Association of myositis and myocarditis in progressive systemic sclerosis","volume":"24","author":"West","year":"1981","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1992.00530360094024","article-title":"Neurologic manifestations of progressive systemic sclerosis","volume":"49","author":"Averbuch-Heller","year":"1992","journal-title":"Arch Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1961.01580150005001","article-title":"Systemic scleroderma, a clinical study of 727 cases","volume":"84","author":"Tuffanelli","year":"1961","journal-title":"Arch Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.55563\/clinexprheumatol\/tt4ilu","article-title":"Diagnostic measures for patients with systemic sclerosis-associated myopathy","volume":"39","author":"Baumberger","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880161110","article-title":"Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma)","volume":"16","author":"Hietaharju","year":"1993","journal-title":"Muscle Nerve."},{"key":"B39","first-page":"525","article-title":"Skeletal muscle involvement","volume-title":"Scleroderma: From pathogenesis to comprehensive management","author":"Mammen","year":"2011"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: An analysis of the EULAR scleroderma trials and research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1987.tb00580.x","article-title":"Scleroderma-polymyositis overlap syndrome. clinical and serologic aspects","volume":"26","author":"Mimori","year":"1987","journal-title":"Int J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10067-004-0975-7","article-title":"Clinical and laboratory features of scleroderma patients developing skeletal myopathy","volume":"24","author":"Mimura","year":"2005","journal-title":"Clin Rheumatol"},{"key":"B43","article-title":"Ultrastructure of muscle microvasculature in progressive systemic sclerosis: Relation to clinical weakness","volume":"10","author":"Russell","year":"1983","journal-title":"J Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"R152","DOI":"10.1186\/ar3888","article-title":"Aldolase predicts subsequent myopathy occurrence in systemic sclerosis","volume":"14","author":"Tol\u00e9dano","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-012-2584-1","article-title":"Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms","volume":"23","author":"Schanz","year":"2013","journal-title":"Eur Radiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-022-02768-z","article-title":"Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis","volume":"24","author":"Ross","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021734","article-title":"Myopathy is a risk factor for poor prognosis of patients with systemic sclerosis: A retrospective cohort study","volume":"99","author":"Zhou","year":"2020","journal-title":"Med (Baltimore)."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000336","article-title":"Myopathy in scleroderma and in other connective tissue diseases","volume":"28","author":"Paik","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"B51","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2730-z","article-title":"Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis","volume":"33","author":"Aguila","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","article-title":"High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22870","article-title":"Independent association of severity of muscle weakness with disability as measured by the health assessment questionnaire disability index in scleroderma","volume":"68","author":"Paik","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390230098013","article-title":"Muscle involvement in the scleroderma syndromes","volume":"150","author":"Ringel","year":"1990","journal-title":"Arch Intern Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"keac361","DOI":"10.1093\/rheumatology\/keac361","article-title":"Clinico-pathological phenotypes of systemic sclerosis associated myopathy: Analysis of a multicenter large cohort","volume":"17","author":"Matas-Garc\u00eda","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008863","article-title":"Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis","volume":"94","author":"Dieudonn\u00e9","year":"2020","journal-title":"Neurology."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa257","article-title":"Refining myositis associated with primary sj\u00f6gren\u2019s syndrome: Data from the prospective cohort ASSESS","volume":"60","author":"Felten","year":"2021","journal-title":"Rheumatol (Oxford)."},{"key":"B62","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1186\/ar4047","article-title":"Impaired skeletal muscle microcirculation in systemic sclerosis","volume":"14","author":"Partovi","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02335-x","article-title":"Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of \u201cscleromyositis.\u201d","volume":"142","author":"Ellezam","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22620","article-title":"Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness: Muscle histopathologic findings in SSc patients with weakness","volume":"67","author":"Paik","year":"2015","journal-title":"Arthritis Care Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31827d8778","article-title":"Dropped head syndrome in a patient with scleromyositis","volume":"19","author":"Fern\u00e1ndez-Serna","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2010.02.015","article-title":"Dropped head syndrome as a presenting sign of scleromyositis","volume":"292","author":"Garcin","year":"2010","journal-title":"J Neurol Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e3181c139f6","article-title":"Paraspinal and scapular myopathy associated with scleroderma","volume":"11","author":"Rojana-Udomsart","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.10.013","article-title":"Dropped head syndrome and systemic sclerosis","volume":"76","author":"Rosato","year":"2009","journal-title":"Joint Bone Spine."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216095","article-title":"Response to: \u201cAnti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis\u201d by campochiaro et\u00a0al","volume":"80","author":"Spielmann","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206812","article-title":"Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: Biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity","volume":"74","author":"Hughes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B71","volume-title":"Haschek and rousseaux\u2019s handbook of toxicologic pathology","author":"Haschek","year":"2013"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23291","article-title":"Association of fibrosing myopathy in systemic sclerosis and higher mortality","volume":"69","author":"Paik","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11926-015-0544-x","article-title":"Role of MRI in diagnosis and management of idiopathic inflammatory myopathies","volume":"17","author":"Maurer","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab553","article-title":"Limb girdle muscular dystrophy R12 (LGMD 2L, anoctaminopathy) mimicking idiopathic inflammatory myopathy: Key points to prevent misdiagnosis","volume":"61","author":"Marago","year":"2022","journal-title":"Rheumatology."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.08.1764","article-title":"MRI Findings in inflammatory muscle diseases and their noninflammatory mimics","volume":"192","author":"Schulze","year":"2009","journal-title":"AJR Am J Roentgenol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-006-0420-1","article-title":"Imaging features of musculoskeletal involvement in systemic sclerosis","volume":"17","author":"Boutry","year":"2007","journal-title":"Eur Radiol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008005","article-title":"Idiopathic inflammatory myopathy: Interrater variability in muscle biopsy reading","volume":"93","author":"Olivier","year":"2019","journal-title":"Neurology."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscular Disord"},{"key":"B79","doi-asserted-by":"publisher","first-page":"102851","DOI":"10.1016\/j.autrev.2021.102851","article-title":"Histopathological features of systemic sclerosis-associated myopathy: A scoping review","volume":"20","author":"Lefebvre","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(80)80396-3","article-title":"Capillary alterations in scleroderma","volume":"2","author":"Fleischmajer","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/life11070610","article-title":"New insights into profibrotic myofibroblast formation in systemic sclerosis: When the vascular wall becomes the enemy","volume":"11","author":"Romano","year":"2021","journal-title":"Life (Basel)."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151425","article-title":"Patients with systemic sclerosis\/polymyositis overlap have a worse survival rate than patients without it","volume":"43","author":"Bhansing","year":"2016","journal-title":"J Rheumatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: A study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheumatic Diseases."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14206","article-title":"Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis","volume":"24","author":"Qiu","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheumatism."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.176.3.2389033","article-title":"Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography","volume":"176","author":"Schurawitzki","year":"1990","journal-title":"Radiology."},{"key":"B87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/23971983211013979","article-title":"Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France","volume":"7","author":"Allanore","year":"2022","journal-title":"J Scleroderma Related Disord"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6362.337","article-title":"Hypoventilatory respiratory failure in generalised scleroderma","volume":"286","author":"Iliffe","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(88)90012-1","article-title":"The lungs in systemic sclerosis (scleroderma): a review and new information","volume":"17","author":"McCarthy","year":"1988","journal-title":"Semin Arthritis Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa322","article-title":"Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease","volume":"60","author":"Nawata","year":"2021","journal-title":"Rheumatol (Oxford)."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab152","article-title":"The clinical phenotype of systemic sclerosis patients with anti-PM\/Scl antibodies: Results from the EUSTAR cohort","volume":"60","author":"Lazzaroni","year":"2021","journal-title":"Rheumatol (Oxford)."},{"key":"B92","doi-asserted-by":"publisher","first-page":"103037","DOI":"10.1016\/j.autrev.2022.103037","article-title":"Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis","volume":"21","author":"Cheng","year":"2022","journal-title":"A systematic review. Autoimmun Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.095836","article-title":"Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients","volume":"68","author":"Hachulla","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B94","article-title":"Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis","volume":"34","author":"Bezante","year":"2007","journal-title":"J Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.09.025","article-title":"Early detection of cardiac involvement in systemic sclerosis: The added value of magnetic resonance imaging","volume":"12","author":"Gargani","year":"2019","journal-title":"JACC Cardiovasc Imaging."},{"key":"B96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12968-016-0289-3","article-title":"Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis","volume":"18","author":"Krumm","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"B97","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/diagnostics9040220","article-title":"Cardiovascular magnetic resonance identifies high-risk systemic sclerosis patients with normal echocardiograms and provides incremental prognostic value","volume":"9","author":"Markousis-Mavrogenis","year":"2019","journal-title":"Diagnostics."},{"key":"B98","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.semarthrit.2017.03.020","article-title":"Cardiovascular magnetic resonance in systemic sclerosis: \u201cPearls and pitfalls.\u201d","volume":"47","author":"Mavrogeni","year":"2017","journal-title":"Semin Arthritis Rheumatism."},{"key":"B99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1532-429X-16-21","article-title":"Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis\u2013a clinical study using myocardial T1-mapping and extracellular volume quantification","volume":"16","author":"Ntusi","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103382","article-title":"Prevalence and factors associated with left ventricular dysfunction in the EULAR scleroderma trial and research group (EUSTAR) database of patients with systemic sclerosis","volume":"69","author":"Allanore","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960161212","article-title":"Myocarditis as a complication in scleroderma patients with myositis","volume":"16","author":"Kerr","year":"1993","journal-title":"Clin Cardiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/38.5.397","article-title":"Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in black south africans","volume":"38","author":"Tager","year":"1999","journal-title":"Rheumatol (Oxford)."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000221","article-title":"Scleroderma renal crisis","volume":"27","author":"Hudson","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B104","article-title":"Glucocorticoids in systemic sclerosis: Weighing the benefits and risks - a systematic review","volume":"31","author":"Iudici","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32831dac75","article-title":"Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: S population-based study","volume":"21","author":"Franck-Larsson","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111582","article-title":"Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients","volume":"39","author":"Sampaio-Barros","year":"2012","journal-title":"J Rheumatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00382-0","article-title":"Esophageal dysfunction in systemic sclerosis: An update","volume":"8","author":"Li","year":"2021","journal-title":"Rheumatol Ther"},{"key":"B108","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11926-019-0841-x","article-title":"GI manifestations with a focus on the esophagus: Recent progress in understanding pathogenesis","volume":"21","author":"T\u00e9treault","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4977-8","article-title":"Intestinal involvement in systemic sclerosis: A clinical review","volume":"63","author":"Sakkas","year":"2018","journal-title":"Dig Dis Sci"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken179","article-title":"The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement","volume":"47","author":"Hunzelmann","year":"2008","journal-title":"Rheumatol (Oxford)."},{"key":"B111","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semarthrit.2007.03.008","article-title":"The impact of psychological functioning upon systemic sclerosis patients\u2019 quality of life","volume":"37","author":"Hyphantis","year":"2007","journal-title":"Semin Arthritis Rheumatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205295","article-title":"Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study","volume":"75","author":"Avouac","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00765-9","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: An unmet clinical need","volume":"18","author":"Herrick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2018.1523455","article-title":"Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: A retrospective cohort study","volume":"48","author":"Peytrignet","year":"2019","journal-title":"Scandinavian J Rheumatol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/rheumatology\/kez299","article-title":"Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity","volume":"59","author":"Zheng","year":"2020","journal-title":"Rheumatol (Oxford)."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","article-title":"Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial","volume":"43","author":"Clements","year":"2000","journal-title":"Arthritis Rheumatol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-020-2113-6","article-title":"Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis","volume":"22","author":"Ledoult","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/art.22721","article-title":"Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model","volume":"56","author":"Shand","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez529","article-title":"Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis","volume":"59","author":"Nevskaya","year":"2020","journal-title":"Rheumatol (Oxford)."},{"key":"B120","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheumatol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/art.38428","article-title":"Clinical and serologic correlates of anti-PM\/Scl antibodies in systemic sclerosis: A multicenter study of 763 patients","volume":"66","author":"D\u2019Aoust","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2011.01688.x","article-title":"South Australian scleroderma register: autoantibodies as predictive biomarkers of phenotype and outcome","volume":"15","author":"Graf","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B125","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370619","article-title":"Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheumatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1186\/ar1729","article-title":"Clinical evaluation of autoantibodies to a novel PM\/Scl peptide antigen","volume":"7","author":"Mahler","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780351014","article-title":"Serum autoantibody to the nucleolar antigen PM-scl. clinical and immunogenetic associations","volume":"35","author":"Oddis","year":"1992","journal-title":"Arthritis Rheumatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2011.592886","article-title":"Distinctive autoantibody profile in Mexican mestizo systemic sclerosis patients","volume":"44","author":"Rodriguez-Reyna","year":"2011","journal-title":"Autoimmunity."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B131","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: Correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.01.013","article-title":"Novel aspects of autoantibodies to the PM\/Scl complex: Clinical, genetic and diagnostic insights","volume":"6","author":"Mahler","year":"2007","journal-title":"Autoimmun Rev"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.07.002","article-title":"Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody","volume":"44","author":"Guillen-Del Castillo","year":"2014","journal-title":"Semin Arthritis Rheumatism."},{"key":"B134","article-title":"Anti-PM-Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B135","article-title":"Anti-pm\/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients","volume":"24","author":"Vandergheynst","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199211000-00001","article-title":"The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-scl","volume":"71","author":"Marguerie","year":"1992","journal-title":"Medicine"},{"key":"B137","article-title":"A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies","volume":"31","author":"Cavazzana","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308089442","article-title":"Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases","volume":"17","author":"Cavazzana","year":"2008","journal-title":"Lupus."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2981-3","article-title":"A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, new Zealand","volume":"34","author":"Chang","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Med (Baltimore)."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes055","article-title":"Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population","volume":"51","author":"Low","year":"2012","journal-title":"Rheumatol (Oxford)."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110295","article-title":"Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap","volume":"68","author":"Mimori","year":"1981","journal-title":"J Clin Invest."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem338","article-title":"Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases","volume":"47","author":"Schild-Poulter","year":"2008","journal-title":"Rheumatol (Oxford)."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.07.005","article-title":"Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis","volume":"12","author":"Villalta","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B146","article-title":"Antibodies against Ku protein in sera from patients with autoimmune diseases","volume":"76","author":"Yaneva","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.05.020","article-title":"Anti-Ku antibodies: Clinical, genetic and diagnostic insights","volume":"9","author":"Belizna","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B148","article-title":"Anti-Ku antibodies in connective tissue diseases: Clinical and serological evaluation of 14 patients","volume":"29","author":"Franceschini","year":"2002","journal-title":"J Rheumatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22163","article-title":"Autoantibodies to RuvBL1 and RuvBL2: A novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement: Novel SSc-related autoantibody directed against RuvBL1\/2","volume":"66","author":"Kaji","year":"2014","journal-title":"Arthritis Care Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Med (Baltimore)."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214439","article-title":"Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes","volume":"78","author":"Spielmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217106","article-title":"Response to: \u201cImmune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies\u201d by yang et\u00a0al","volume":"81","author":"Spielmann","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00961.x","article-title":"Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis","volume":"117","author":"Ihn","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/37.1.39","article-title":"Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis","volume":"37","author":"Jacobsen","year":"1998","journal-title":"Br J Rheumatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.20268","article-title":"Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants","volume":"30","author":"Reveille","year":"2001","journal-title":"Semin Arthritis Rheumatism."},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12028.x","article-title":"The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis","volume":"120","author":"Asano","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/art.39432","article-title":"Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension","volume":"68","author":"Sobanski","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/art.24409","article-title":"Anti-U3 RNP autoantibodies in systemic sclerosis","volume":"60","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390712","article-title":"Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). an immunogenetic, serologic, and clinical analysis","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheumatol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350415","article-title":"Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease","volume":"35","author":"Hirakata","year":"1992","journal-title":"Arthritis Rheumatol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/art.1780350114","article-title":"Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis","volume":"35","author":"Okano","year":"1992","journal-title":"Arthritis Rheumatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-fibrillarin antibodies in systemic sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatol (Oxford)."},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/art.10729","article-title":"Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex","volume":"48","author":"Yang","year":"2003","journal-title":"Arthritis Rheumatol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310409","article-title":"Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma)","volume":"31","author":"Reimer","year":"1988","journal-title":"Arthritis Rheumatol"},{"key":"B165","article-title":"Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin)","volume":"27","author":"Falkner","year":"2000","journal-title":"J Rheumatol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220004","article-title":"Anti-RuvBL1\/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern","volume":"81","author":"Vulsteke","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001357","article-title":"Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies","volume":"6","author":"Landon-Cardinal","year":"2020","journal-title":"RMD Open"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/art.30349","article-title":"Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of d, e, f, and G proteins without other components of small nuclear ribonucleoproteins","volume":"63","author":"Satoh","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/rheumatology\/kex392","article-title":"Autoantibodies to the survival of motor neuron complex in a patient with necrotizing autoimmune myopathy","volume":"57","author":"Amlani","year":"2018","journal-title":"Rheumatol (Oxford)."},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B171","article-title":"Anti-SMN autoantibodies are associated with systemic sclerosis small bowel involvement in anti-U1RNP positive autoimmune myositis [abstract]","volume":"72","author":"Vo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B172","article-title":"Anti-SMN autoantibodies in mixed connective tissue disease are associated with a scleromyositis phenotype [abstract]","volume":"74","author":"El Kamouni","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"102211","DOI":"10.1016\/j.coph.2022.102211","article-title":"Current advances in the treatment of systemic sclerosis","volume":"64","author":"Bukiri","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000784","article-title":"Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]","volume":"4","author":"Meyer","year":"2018","journal-title":"RMD Open"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000782","article-title":"Systemic sclerosis: state of the art on clinical practice guidelines","volume":"4","author":"Smith","year":"2018","journal-title":"RMD Open"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheumatol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1697-6","article-title":"Corticosteroids and the risk of scleroderma renal crisis: A systematic review","volume":"32","author":"Trang","year":"2012","journal-title":"Rheumatol Int"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies zandvoort, the Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B184","doi-asserted-by":"publisher","first-page":"102431","DOI":"10.1016\/j.autrev.2019.102431","article-title":"Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients","volume":"19","author":"Chaigne","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05075-z","article-title":"Rituximab and intravenous immunoglobulin treatment in PM\/Scl antibody-associated disease: Case-based review","volume":"42","author":"Srikantharajah","year":"2022","journal-title":"Rheumatol Int"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: Results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155282","article-title":"Machine-learning classification identifies early systemic sclerosis patients that improve with abatacept treatment by modulating CD28-pathways","volume":"7","author":"Mehta","year":"2022","journal-title":"JCI Insight"},{"key":"B191","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/annrheumdis-2022-eular.7","article-title":"Pos0839 randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of Sc abatacept in adults with active idiopathic inflammatory","volume":"81","author":"Aggarwal","year":"2022","journal-title":"Myopathy Ann Rheumatic Dis"},{"key":"B192","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA."},{"key":"B194","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in caucasians with myositis identifies significant associations with autoantibody subgroups","volume":"78","author":"Rothwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B195","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejim.2022.04.017","article-title":"Epidemiological and genetic features of anti-3\u2212hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review","volume":"101","author":"Prieto-Pe\u00f1a","year":"2022","journal-title":"Eur J Intern Med"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"B197","doi-asserted-by":"publisher","first-page":"105115","DOI":"10.1016\/j.jbspin.2020.105115","article-title":"HLA association with the susceptibility to anti-synthetase syndrome","volume":"88","author":"Remuzgo-Mart\u00ednez","year":"2021","journal-title":"Joint Bone Spine."},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab423","article-title":"Significance of sj\u00f6gren\u2019s syndrome and anti-cN1A antibody in myositis patients","volume":"61","author":"Levy","year":"2021","journal-title":"Rheumatology"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.10.1067","article-title":"Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases","volume":"36","author":"Garton","year":"1997","journal-title":"Br J Rheumatol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320918021","article-title":"Inflammatory myositis in systemic lupus erythematosus","volume":"29","author":"Bitencourt","year":"2020","journal-title":"Lupus."},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1191\/0961203302lu186oa","article-title":"SLE\/myositis overlap: are the manifestations of SLE different in overlap disease","volume":"11","author":"Dayal","year":"2002","journal-title":"Lupus"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1136\/ard.53.3.178","article-title":"Muscle biopsy abnormalities in systemic lupus erythematosus: correlation with clinical and laboratory parameters","volume":"53","author":"Lim","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.4.440","article-title":"Primary sj\u00f6gren\u2019s syndrome associated with inclusion body myositis","volume":"41","author":"Kanellopoulos","year":"2002","journal-title":"Rheumatol (Oxford)."},{"key":"B204","article-title":"Myositis in primary sj\u00f6gren\u2019s syndrome: data from a multicentre cohort","volume":"33","author":"Colafrancesco","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.4081\/cp.2011.e89","article-title":"Systemic lupus erythematosusmyositis overlap syndrome: Report of 6 cases","volume":"1","author":"Maazoun","year":"2011","journal-title":"Clin Pract"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007188","article-title":"Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies","volume":"92","author":"Casal-Dominguez","year":"2019","journal-title":"Neurology."},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1053\/S0049-0172(03)00133-1","article-title":"Clusters of clinical and immunologic features in systemic lupus erythematosus: Analysis of 600 patients from a single center","volume":"33","author":"Font","year":"2004","journal-title":"Semin Arthritis Rheumatism."},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: A randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: A systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology."},{"key":"B211","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s40478-022-01443-3","article-title":"Inclusion body myositis and sj\u00f6gren\u2019s syndrome: The association works both ways","volume":"10","author":"Giannini","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"B212","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40478-022-01389-6","article-title":"Inclusion body myositis and associated diseases: An argument for shared immune pathologies","volume":"10","author":"Nelke","year":"2022","journal-title":"Acta Neuropathol Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.974078\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T09:54:10Z","timestamp":1674726850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.974078\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":212,"alternative-id":["10.3389\/fimmu.2022.974078"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.974078","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"974078"}}